ES2301178T3 - Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. - Google Patents
Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. Download PDFInfo
- Publication number
- ES2301178T3 ES2301178T3 ES97922294T ES97922294T ES2301178T3 ES 2301178 T3 ES2301178 T3 ES 2301178T3 ES 97922294 T ES97922294 T ES 97922294T ES 97922294 T ES97922294 T ES 97922294T ES 2301178 T3 ES2301178 T3 ES 2301178T3
- Authority
- ES
- Spain
- Prior art keywords
- alfavirus
- vector
- recombinant
- rna
- based vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Secondary Cells (AREA)
Abstract
SE EXPONEN MOLECULAS AISLADAS DE ACIDO NUCLEICO, QUE COMPRENDEN UN GEN DE PROTEINA NO ESTRUCTURAL DEL ALFAVIRUS QUE, CUANDO PUEDE INCORPORARSE FACILMENTE A UNA PARTICULA DE ALFAVIRUS RECOMBINANTE, UN SISTEMA DE INICIACION DE VECTORES EN CAPAS EUCARIOTICAS, O UNA REPLICACION DEL VECTOR DEL RNA, TIENEN UN NIVEL REDUCIDO DE SINTESIS DEL RNA ESPECIFICAS DEL VECTOR, EN COMPARACION CON EL TIPO SILVESTRE, Y EL MISMO NIVEL O UN NIVEL SUPERIOR DE PROTEINAS CODIFICADAS POR RNA TRANSCRITO A PARTIR DEL PROMOTOR DE LA REGION DE UNION VIRAL, COMPARADO CON UNA PARTICULA DE ALFAVIRUS RECOMBINANTE DEL TIPO SILVESTRE. SE EXPONEN IGUALMENTE LAS REPLICAS DE VECTORES DEL RNA, CONSTRUCCIONES DE VECTORES DEL ALFAVIRUS Y SISTEMA DE INICIACION DE VECTORES EN CAPAS EUCARIOTICAS QUE CONTIENEN LAS MOLECULAS DE ACIDO NUCLEICO ARRIBA IDENTIFICADAS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62859496A | 1996-04-05 | 1996-04-05 | |
| US66895396A | 1996-06-24 | 1996-06-24 | |
| US67964096A | 1996-07-12 | 1996-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2301178T3 true ES2301178T3 (es) | 2008-06-16 |
Family
ID=27417454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97922294T Expired - Lifetime ES2301178T3 (es) | 1996-04-05 | 1997-04-04 | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP1997900A3 (es) |
| JP (2) | JP4383530B2 (es) |
| AT (1) | ATE386811T1 (es) |
| AU (1) | AU2800797A (es) |
| DE (1) | DE69738521T2 (es) |
| ES (1) | ES2301178T3 (es) |
| WO (1) | WO1997038087A2 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| EP0996737A1 (en) * | 1997-08-15 | 2000-05-03 | Inex Pharmaceuticals Corp. | Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells |
| AU757549B2 (en) | 1998-03-27 | 2003-02-27 | Cytos Biotechnology Ag | Inducible alphaviral gene expression system |
| JP2002521461A (ja) * | 1998-07-29 | 2002-07-16 | インビトロゲン・コーポレーション | Rnaウイルスを用いる組換えタンパク質の調節発現 |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| WO2000039318A1 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US6423544B1 (en) | 1998-12-31 | 2002-07-23 | Chiron Corporation | Compositions and methods for producing recombinant virions |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| CA2373300C (en) * | 1999-04-14 | 2012-02-21 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| WO2001042442A2 (en) | 1999-12-10 | 2001-06-14 | Cytos Biotechnology Ag | Activation of endogenous genes by genomic introduction of a replicon |
| US6767699B2 (en) | 2000-05-31 | 2004-07-27 | Chiron Corporation | Method for the quantitation of alphavirus replicon particles |
| WO2002020721A2 (en) | 2000-09-07 | 2002-03-14 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| WO2002026212A2 (en) | 2000-09-28 | 2002-04-04 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
| AU2002305914A1 (en) * | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| EP1409694A4 (en) | 2001-07-05 | 2006-02-08 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP1386926A1 (en) * | 2002-07-29 | 2004-02-04 | Bioxtal | Methods for producing labelled recombinant polypeptides and uses thereof |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
| US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| AU2005327198B2 (en) | 2004-07-09 | 2011-03-31 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| WO2006050394A2 (en) | 2004-11-01 | 2006-05-11 | Novartis Vaccines And Diagnostics Inc. | Combination approaches for generating immune responses |
| EP1856250B1 (en) | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| EP1945247A1 (en) | 2005-10-18 | 2008-07-23 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| JP5036741B2 (ja) * | 2009-02-18 | 2012-09-26 | 中原大學 | 翻訳段階で自己切断活性を有するポリヌクレオチド配列を同定するための方法およびシステム |
| CN102933267B (zh) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | 交互式混合异步计算机游戏基础结构 |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| AU2013266496B2 (en) | 2012-05-21 | 2018-08-09 | The Regents Of The University Of California | Generation of human iPS cells by a synthetic self- replicative RNA |
| ES2523016B1 (es) | 2013-05-20 | 2015-09-09 | 3P Biopharmaceuticals | Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes |
| EP2878674A1 (en) | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| TWI791459B (zh) * | 2016-08-10 | 2023-02-11 | 日商領先基因生技股份有限公司 | 改變真核細胞基因體的標的部位之方法 |
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| NL2022538B1 (en) | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
| US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| WO2024124190A1 (en) | 2022-12-09 | 2024-06-13 | Microbial Machines, Inc. | Engineered microorganisms for delivery of therapeutic agents |
| WO2024263805A1 (en) | 2023-06-21 | 2024-12-26 | Microbial Machines, Inc. | Genetically engineered microorganisms for detection of diseased cells |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA802992B (en) | 1979-06-01 | 1981-10-28 | Univ California | Human pre-growth hormone |
| GR70279B (es) | 1979-09-12 | 1982-09-03 | Univ California | |
| US4431740A (en) | 1979-09-12 | 1984-02-14 | The Regents Of The University Of California | DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
| US4745069A (en) | 1982-05-25 | 1988-05-17 | Eli Lilly And Company | Cloning vectors for expression of exogenous protein |
| JPS5936698A (ja) | 1982-08-20 | 1984-02-28 | Science & Tech Agency | B型肝炎ウイルス遺伝子を組込んだ組換えdnaおよび形質転換動物細胞 |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
| US4696898A (en) | 1984-01-16 | 1987-09-29 | Integrated Genetics, Inc. | Vector encoding hepatitis B surface antigen |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| EP0174835A1 (en) | 1984-09-11 | 1986-03-19 | The Upjohn Company | Human tissue plasminogen activator and recombinant DNA compounds |
| EP0201153A3 (en) | 1985-02-09 | 1987-10-07 | Beecham Group Plc | Modified enzyme and process for its preparation |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| JPS62236493A (ja) | 1986-04-08 | 1987-10-16 | Green Cross Corp:The | HBウイルスのPre S領域を含むHBsAgの製造方法 |
| EP0307402B1 (en) | 1986-05-06 | 1993-08-11 | Genetics Institute, Inc. | Production of m-csf |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ZA88488B (en) | 1987-01-30 | 1988-10-26 | Smith Kline Rit | Hepatitis b virus surface antigens and hybrid antigens containing them |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| DK275788A (da) | 1987-05-22 | 1989-02-03 | Zymogenetics Inc | Fibrinolytiske proteiner |
| WO1988010301A1 (en) | 1987-06-22 | 1988-12-29 | Mccormick And Jones Engineering Ltd. | Hepatitis b surface antigen vaccine |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| CA2004261A1 (en) | 1988-12-01 | 1990-06-01 | Charles T. Tackney | Synthetic interleukin-6 |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5240845A (en) | 1989-07-11 | 1993-08-31 | Otsuka Pharmaceutical Factory, Ltd. | Mutated streptokinase proteins |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| IL95511A (en) | 1989-08-30 | 2000-10-31 | Max Planck Gesellschaft | Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor |
| IE903130A1 (en) | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| AU3074992A (en) | 1991-11-14 | 1993-06-15 | Amgen, Inc. | Expression of neurotrophic factors with heterologous prepro regions |
| ATE152915T1 (de) | 1991-11-29 | 1997-05-15 | Viagene Inc | Immuntherapeutische vektorkonstrukte gegen krebs |
| ATE219522T1 (de) | 1992-02-04 | 2002-07-15 | Chiron Corp | Hepatistherapeutikum |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| US5631148A (en) | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
| US5580967A (en) | 1994-05-13 | 1996-12-03 | The Scripps Research Institute | Optimized catalytic DNA-cleaving ribozymes |
-
1997
- 1997-04-04 ES ES97922294T patent/ES2301178T3/es not_active Expired - Lifetime
- 1997-04-04 AT AT97922294T patent/ATE386811T1/de active
- 1997-04-04 EP EP08075018A patent/EP1997900A3/en not_active Withdrawn
- 1997-04-04 JP JP53651297A patent/JP4383530B2/ja not_active Expired - Fee Related
- 1997-04-04 EP EP97922294A patent/EP0907746B1/en not_active Expired - Lifetime
- 1997-04-04 AU AU28007/97A patent/AU2800797A/en not_active Abandoned
- 1997-04-04 WO PCT/US1997/006010 patent/WO1997038087A2/en not_active Ceased
- 1997-04-04 DE DE69738521T patent/DE69738521T2/de not_active Expired - Lifetime
-
2008
- 2008-05-08 JP JP2008122803A patent/JP2008200051A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2800797A (en) | 1997-10-29 |
| DE69738521D1 (de) | 2008-04-03 |
| DE69738521T2 (de) | 2009-05-07 |
| EP1997900A3 (en) | 2010-10-06 |
| WO1997038087A2 (en) | 1997-10-16 |
| EP0907746B1 (en) | 2008-02-20 |
| JP4383530B2 (ja) | 2009-12-16 |
| EP0907746A2 (en) | 1999-04-14 |
| EP1997900A2 (en) | 2008-12-03 |
| JP2001521369A (ja) | 2001-11-06 |
| ATE386811T1 (de) | 2008-03-15 |
| WO1997038087A3 (en) | 1998-03-12 |
| JP2008200051A (ja) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR19C1020I1 (fr) | Nouvelles molecules b7-4 et leurs utilisations | |
| ATE386811T1 (de) | Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen | |
| DE69834267D1 (de) | Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen | |
| DE60035517D1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
| EP0653940A4 (en) | GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE. | |
| DE69535703D1 (de) | Aav-vermittelte überbringung von dna in zellen des nervensystems | |
| BR0010725A (pt) | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc | |
| DE69431805D1 (de) | Struktur höherer ordnung und bindung von peptidnukleinsäuren | |
| DE69840230D1 (de) | Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren | |
| DE69841723D1 (de) | Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna | |
| WO2003042362A8 (en) | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR | |
| DE69504808D1 (de) | Corticotropin freisetzende rezeptoren des faktor 2 | |
| DK1144600T3 (da) | Akt-3-nukleinsyre, polypeptider og anvendelser deraf | |
| FR2710074B1 (fr) | Gène GRB3-3, ses variants et leurs utilisations. | |
| FI971896A0 (fi) | BMP-tyyppi II-reseptoria koodaava cDNA | |
| BR9811853A (pt) | Processos para aumentar o rendimento em plantas | |
| ATE480620T1 (de) | Neue pgc-1-isoformen und deren verwendungen | |
| NO951315D0 (no) | Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler | |
| ATE229074T1 (de) | Rekombinante chladosporium herbarum allergene | |
| WO2000044898A3 (en) | Novel agouti and agouti-related peptide analogs | |
| DE60142356D1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
| BR0010222A (pt) | Vetores de expressão viral | |
| AR006641A1 (es) | Molecula de acido nucleico que codifica un peptido inmunoreactivo, un vector de expresion mamifero, una particula viral, una celula de mamifero, unmetodo para producir un peptido inmunoreactivo, un metodo para modular la respuesta inmune, el uso de la molecula de acido nucleico en terapia y una | |
| BR9914130A (pt) | Promotores de plantas e terminadores de plantas | |
| CO5070672A1 (es) | Polipeptido de proteina c humana |